Schedule 13G ownership disclosure

Denali Therapeutics Inc

Common Stock · CUSIP: 24823R105

Event date: 2024-12-31

Filing-level shares
5,477,211.00
Percent of class
3.8%
  • Capital Research Global Investors

    Shares: 5,477,211.00 · Class: 3.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001422848-25-000029
Form type
SCHEDULE 13G/A
Filer
Capital Research Global Investors
CIK
CIK 1422848
Filed
Feb 13, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub